Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...